Jessica Burtell

机构：Prelude Therapeutics Incorporated (United States) · ORCID：0000-0002-7763-6379

发表论文 50 篇 · 总被引 67 次 · h-index 3

代表论文

• PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies (2023 · Cancer Research Communications · 被引 38)
• PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers (2025 · Cancer Research · 被引 20)
• Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers (2023 · Molecular Cancer Therapeutics · 被引 4)
• Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2 (2024 · Cancer Research · 被引 3)
• Abstract 1649: Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models (2025 · Cancer Research · 被引 1)
• Abstract 6270: Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers (2023 · Cancer Research · 被引 1)